Efficacy and Safety of Rufinamide Adjunctive Therapy in Patients with Lennox–Gastaut Syndrome (LGS): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Trial
Аннотация:The Late Breaking Science Abstracts were originally presented at the 57th American Academy of Neurology Annual Meeting in Miami Beach, FL. These abstracts highlight the most current research by neurologists, neuroscientists, and other applicable researchers whose work is of major scientific importance or interest, warranting expedited presentation and publication. Key aspects of the research must have been conducted after the November 3 abstract deadline. Because of the late deadline for these abstracts, they were not included in the Program Issue.
To evaluate the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut (LGS) syndrome.
Lennox-Gastaut syndrome is a catastrophic childhood epileptic encephalopathy characterized by multiple types of treatment resistant seizures. Despite the demonstrated efficacy of a few newer antiepileptic medications (AEDs) for patients with LGS, significant numbers of LGS patients continue to experience seizures. Due to its potential broad spectrum of activity against seizures and the …
